氧化樟脑注射液联合环磷腺苷葡胺治疗心力衰竭的临床研究

Clinical study on Vitacamphorae Injection combined with meglumine adenosine cyclophosphate in treatment of heart failure

目的探讨氧化樟脑注射液联合环磷腺苷葡胺治疗心力衰竭的临床疗效。方法选取2016年9月—2017年9月在哈尔滨医科大学附属第四医院治疗的心力衰竭患者86例,随机分为对照组(43例)和治疗组(43例)。对照组静脉滴注环磷腺苷葡胺注射液,180 mg加入5%葡萄糖注射液500 mL,1次/d;治疗组在对照组基础上肌肉注射氧化樟脑注射液,2 mL/次,1次/d。两组均治疗2周。观察两组患者临床疗效,同时比较治疗前后两组患者心功能指标和血清细胞因子水平。结果治疗后,对照组和治疗组临床总有效率分别为83.72%和97.67%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组左室舒张末期内径(LVEDD)、左心室收缩末期容积(LVESV)和左心室收缩末期内径(LVESD)均显著降低(P<0.05),左心室射血分数(LVEE)显著升高(P<0.05),且治疗组心功能明显优于对照组(P<0.05)。治疗后,两组血清氨基末端脑钠肽前体(NT-proBNP)、β内啡肽(β-EP)、白细胞介素-1β(IL-1β)、肌钙蛋白(cTnT)水平显著降低(P<0.05),血管内皮生长因子(VEGF)和类胰岛素一号增长因子(IGF-1)水平显著升高(P<0.05),且治疗组上述血清细胞因子水平明显优于对照组(P<0.05)。结论氧化樟脑注射液联合环磷腺苷葡胺治疗心力衰竭效果显著,可有效改善患者心功能,降低机体炎症反应,从而降低心肌重塑风险。

Objective To investigate the clinical efficacy of Vitacamphorae Injection combined with meglumine adenosine cyclophosphate in treatment of heart failure. Methods Patients(86 cases) with heart failure in the Fourth Affiliated Hospital of Harbin Medical University from September 2016 to September 2017 were randomly divided into control(43 cases) and treatment(43 cases) groups. Patients in the control group were iv administered with Meglumine Adenosine Cyclophosphate Injection, 180 mg added into 5% glucose injection 500 mL, once daily. Patients in the treatment group were im administered with Vitacamphorae Injection on the basis of the control group, 2 mL/time, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the cardiac function indicators, and the serum cytokines levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 83.72% and 97.67%, respectively, and there were differences between two groups(P < 0.05). After treatment, the LVEDD, LVESV and LVESD in two groups were significantly decreased(P < 0.05), but LVEE was significantly increased(P < 0.05), and the cardiac function in the treatment group was significantly better than that in the control group(P < 0.05). After treatment, the serum NT-proBNP, cTnT, β-EP and IL-1β levels in two groups were significantly decreased(P < 0.05), but VEGF and IGF-1 levels were significantly increased(P < 0.05), and these serum cytokines levels in the treatment group were significantly better than those in the control group(P < 0.05). Conclusion Vitacamphorae Injection combined with meglumine adenosine cyclophosphate has remarkable clinical effect in treatment of heart failure, which can effectively improve the heart function and reduce the inflammatory response, reduce the risk of myocardial remodeling.